Academic Journal
Προβολή σε EDS

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
Συγγραφείς: Paydar I; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Pepin A; George Washington University , Washington, DC , USA., Cyr RA; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., King J; University of South Carolina School of Medicine , Columbia, SC , USA., Yung TM; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Bullock EG; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Lei S; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Satinsky A; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Harter KW; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Suy S; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Dritschilo A; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Lynch JH; Department of Urology, Georgetown University Hospital , Washington, DC , USA., Kole TP; Department of Radiation Oncology, The Valley Hospital , Ridgewood, NJ , USA., Collins SP; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.
Πηγή: Frontiers in oncology [Front Oncol] 2017 Feb 07; Vol. 7, pp. 5. Date of Electronic Publication: 2017 Feb 07 (Print Publication: 2017).
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Imprint Name(s): Original Publication: [Lausanne : Frontiers Research Foundation]
Περίληψη: Background: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone. Stereotactic body radiation therapy (SBRT) may be a less invasive alternative to brachytherapy boost. Here, we report the 3-year gastrointestinal (GI) and genitourinary (GU) toxicities of IMRT plus SBRT boost.
Materials and Methods: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by fiducial-guided IMRT (45-50.4 Gy) on an institutional protocol. Toxicity was prospectively graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) at the start of and at 1- to 6-month intervals after therapy. Rectal telangiectasias were graded using the Vienna Rectoscopy Score (VRS).
Results: At a median follow-up of 4.2 years (2.4-7.5), 108 patients (4 low-, 45 intermediate-, and 59 high-risk) with a median age of 74 years (55-92) were treated with SBRT plus IMRT, with 8% on anticoagulation and an additional 48% on antiplatelet therapy at the start of therapy. The cumulative incidence of late ≥grade 2 GI toxicity was 12%. Of these, 7% were due to late rectal bleeding, with six patients requiring up to two coagulation procedures. One patient with rectal telangiectasias was treated with hyperbaric oxygen (grade 3 toxicity). No rectal fistulas or stenoses were observed. Ten patients had multiple non-confluent telangiectasias (VRS grade 2), and three patients had multiple confluent telangiectasias (VRS grade 3). The cumulative incidence of late grade 3 GU toxicity was 6%. Most late toxicities were due to hematuria requiring bladder fulguration. There were no late ≥grade 4 GU toxicities.
Conclusion: Rates of clinically significant GI and GU toxicities are modest following IMRT plus SBRT boost. Future studies should compare cancer control, quality of life, and toxicity with other treatment modalities for patients with high-risk prostate cancer.
References: Technol Cancer Res Treat. 2010 Oct;9(5):453-62. (PMID: 20815416)
Front Oncol. 2016 May 06;6:114. (PMID: 27200300)
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):150-4. (PMID: 16111583)
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):937-9. (PMID: 26530768)
Radiother Oncol. 1998 Mar;46(3):285-95. (PMID: 9572622)
J Urol. 2015 Dec;194(6):1624-30. (PMID: 26165583)
Radiat Oncol. 2016 Jan 21;11:8. (PMID: 26792201)
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9. (PMID: 22330997)
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8. (PMID: 20207506)
Technol Cancer Res Treat. 2010 Dec;9(6):575-82. (PMID: 21070079)
J Clin Oncol. 2005 Feb 20;23(6):1192-9. (PMID: 15718316)
Radiother Oncol. 2012 Jul;104(1):114-8. (PMID: 22727264)
Radiat Oncol. 2013 Mar 13;8:58. (PMID: 23497695)
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55. (PMID: 15001244)
J Clin Oncol. 2006 May 1;24(13):1990-6. (PMID: 16648499)
Urology. 2000 Dec 20;56(6):899-905. (PMID: 11113727)
Acta Oncol. 2005;44(3):265-76. (PMID: 16076699)
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27. (PMID: 12023135)
Cancer. 2015 Jul 15;121(14):2422-30. (PMID: 25847819)
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007. (PMID: 16750320)
Urology. 2000 Mar;55(3):382-6. (PMID: 10699615)
Radiat Oncol. 2013 Jan 31;8:30. (PMID: 23369294)
Radiother Oncol. 2012 May;103(2):217-22. (PMID: 22341794)
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82. (PMID: 21300474)
Cancer. 2013 Feb 1;119(3):681-90. (PMID: 22893254)
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7. (PMID: 18947938)
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74. (PMID: 17765406)
Cancer. 1999 Jun 15;85(12):2630-7. (PMID: 10375112)
J Urol. 2016 Jun;195(6):1811-6. (PMID: 26778712)
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85. (PMID: 22954770)
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-53. (PMID: 27325475)
Radiother Oncol. 2000 Jan;54(1):11-9. (PMID: 10719695)
Radiat Oncol. 2014 Jan 01;9:1. (PMID: 24382205)
Br J Radiol. 2015 Oct;88(1054):20140736. (PMID: 26235142)
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92 (5):971-7. (PMID: 26054865)
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8. (PMID: 24113055)
Front Oncol. 2014 Oct 31;4:278. (PMID: 25401085)
J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7. (PMID: 14610406)
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55. (PMID: 17531401)
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16. (PMID: 15817332)
Radiat Oncol. 2014 Dec 12;9:277. (PMID: 25497602)
Radiother Oncol. 2009 May;91(2):232-6. (PMID: 19097660)
J Clin Oncol. 2007 Dec 1;25(34):5366-73. (PMID: 18048817)
JAMA. 2005 Sep 14;294(10):1233-9. (PMID: 16160131)
Front Oncol. 2015 Sep 01;5:194. (PMID: 26389077)
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):184-91. (PMID: 12694837)
J Urol. 2007 Jan;177(1):123-7; discussion 127. (PMID: 17162020)
Grant Information: P30 CA051008 United States CA NCI NIH HHS
Contributed Indexing: Keywords: CyberKnife; IMRT; SBRT; common terminology criteria; prostate cancer
Entry Date(s): Date Created: 20170223 Latest Revision: 20220408
Update Code: 20260130
PubMed Central ID: PMC5293802
DOI: 10.3389/fonc.2017.00005
PMID: 28224113
Βάση Δεδομένων: MEDLINE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:cmedm&genre=article&issn=2234943X&ISBN=&volume=7&issue=&date=20170207&spage=5&pages=5&title=Frontiers in oncology&atitle=Intensity-Modulated%20Radiation%20Therapy%20with%20Stereotactic%20Body%20Radiation%20Therapy%20Boost%20for%20Unfavorable%20Prostate%20Cancer%3A%20A%20Report%20on%203-Year%20Toxicity.&aulast=Paydar%20I&id=DOI:10.3389/fonc.2017.00005
    Name: Full Text Finder (for New FTF UI) (ns324271)
    Category: fullText
    Text: Full Text Finder
    MouseOverText: Full Text Finder
Header DbId: cmedm
DbLabel: MEDLINE
An: 28224113
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Paydar+I%22">Paydar I</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Pepin+A%22">Pepin A</searchLink>; George Washington University , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Cyr+RA%22">Cyr RA</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22King+J%22">King J</searchLink>; University of South Carolina School of Medicine , Columbia, SC , USA.<br /><searchLink fieldCode="AU" term="%22Yung+TM%22">Yung TM</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Bullock+EG%22">Bullock EG</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Lei+S%22">Lei S</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Satinsky+A%22">Satinsky A</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Harter+KW%22">Harter KW</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Suy+S%22">Suy S</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Dritschilo+A%22">Dritschilo A</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Lynch+JH%22">Lynch JH</searchLink>; Department of Urology, Georgetown University Hospital , Washington, DC , USA.<br /><searchLink fieldCode="AU" term="%22Kole+TP%22">Kole TP</searchLink>; Department of Radiation Oncology, The Valley Hospital , Ridgewood, NJ , USA.<br /><searchLink fieldCode="AU" term="%22Collins+SP%22">Collins SP</searchLink>; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2017 Feb 07; Vol. 7, pp. 5. <i>Date of Electronic Publication: </i>2017 Feb 07 (<i>Print Publication: </i>2017).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: <i>Original Publication</i>: [Lausanne : Frontiers Research Foundation]
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone. Stereotactic body radiation therapy (SBRT) may be a less invasive alternative to brachytherapy boost. Here, we report the 3-year gastrointestinal (GI) and genitourinary (GU) toxicities of IMRT plus SBRT boost.<br />Materials and Methods: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by fiducial-guided IMRT (45-50.4 Gy) on an institutional protocol. Toxicity was prospectively graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) at the start of and at 1- to 6-month intervals after therapy. Rectal telangiectasias were graded using the Vienna Rectoscopy Score (VRS).<br />Results: At a median follow-up of 4.2 years (2.4-7.5), 108 patients (4 low-, 45 intermediate-, and 59 high-risk) with a median age of 74 years (55-92) were treated with SBRT plus IMRT, with 8% on anticoagulation and an additional 48% on antiplatelet therapy at the start of therapy. The cumulative incidence of late ≥grade 2 GI toxicity was 12%. Of these, 7% were due to late rectal bleeding, with six patients requiring up to two coagulation procedures. One patient with rectal telangiectasias was treated with hyperbaric oxygen (grade 3 toxicity). No rectal fistulas or stenoses were observed. Ten patients had multiple non-confluent telangiectasias (VRS grade 2), and three patients had multiple confluent telangiectasias (VRS grade 3). The cumulative incidence of late grade 3 GU toxicity was 6%. Most late toxicities were due to hematuria requiring bladder fulguration. There were no late ≥grade 4 GU toxicities.<br />Conclusion: Rates of clinically significant GI and GU toxicities are modest following IMRT plus SBRT boost. Future studies should compare cancer control, quality of life, and toxicity with other treatment modalities for patients with high-risk prostate cancer.
– Name: Ref
  Label: References
  Group: RefInfo
  Data: Technol Cancer Res Treat. 2010 Oct;9(5):453-62. (PMID: <searchLink fieldCode="PM" term="%2220815416%22">20815416)</searchLink><br />Front Oncol. 2016 May 06;6:114. (PMID: <searchLink fieldCode="PM" term="%2227200300%22">27200300)</searchLink><br />Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):150-4. (PMID: <searchLink fieldCode="PM" term="%2216111583%22">16111583)</searchLink><br />Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):937-9. (PMID: <searchLink fieldCode="PM" term="%2226530768%22">26530768)</searchLink><br />Radiother Oncol. 1998 Mar;46(3):285-95. (PMID: <searchLink fieldCode="PM" term="%229572622%22">9572622)</searchLink><br />J Urol. 2015 Dec;194(6):1624-30. (PMID: <searchLink fieldCode="PM" term="%2226165583%22">26165583)</searchLink><br />Radiat Oncol. 2016 Jan 21;11:8. (PMID: <searchLink fieldCode="PM" term="%2226792201%22">26792201)</searchLink><br />Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9. (PMID: <searchLink fieldCode="PM" term="%2222330997%22">22330997)</searchLink><br />Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8. (PMID: <searchLink fieldCode="PM" term="%2220207506%22">20207506)</searchLink><br />Technol Cancer Res Treat. 2010 Dec;9(6):575-82. (PMID: <searchLink fieldCode="PM" term="%2221070079%22">21070079)</searchLink><br />J Clin Oncol. 2005 Feb 20;23(6):1192-9. (PMID: <searchLink fieldCode="PM" term="%2215718316%22">15718316)</searchLink><br />Radiother Oncol. 2012 Jul;104(1):114-8. (PMID: <searchLink fieldCode="PM" term="%2222727264%22">22727264)</searchLink><br />Radiat Oncol. 2013 Mar 13;8:58. (PMID: <searchLink fieldCode="PM" term="%2223497695%22">23497695)</searchLink><br />Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55. (PMID: <searchLink fieldCode="PM" term="%2215001244%22">15001244)</searchLink><br />J Clin Oncol. 2006 May 1;24(13):1990-6. (PMID: <searchLink fieldCode="PM" term="%2216648499%22">16648499)</searchLink><br />Urology. 2000 Dec 20;56(6):899-905. (PMID: <searchLink fieldCode="PM" term="%2211113727%22">11113727)</searchLink><br />Acta Oncol. 2005;44(3):265-76. (PMID: <searchLink fieldCode="PM" term="%2216076699%22">16076699)</searchLink><br />Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27. (PMID: <searchLink fieldCode="PM" term="%2212023135%22">12023135)</searchLink><br />Cancer. 2015 Jul 15;121(14):2422-30. (PMID: <searchLink fieldCode="PM" term="%2225847819%22">25847819)</searchLink><br />Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007. (PMID: <searchLink fieldCode="PM" term="%2216750320%22">16750320)</searchLink><br />Urology. 2000 Mar;55(3):382-6. (PMID: <searchLink fieldCode="PM" term="%2210699615%22">10699615)</searchLink><br />Radiat Oncol. 2013 Jan 31;8:30. (PMID: <searchLink fieldCode="PM" term="%2223369294%22">23369294)</searchLink><br />Radiother Oncol. 2012 May;103(2):217-22. (PMID: <searchLink fieldCode="PM" term="%2222341794%22">22341794)</searchLink><br />Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82. (PMID: <searchLink fieldCode="PM" term="%2221300474%22">21300474)</searchLink><br />Cancer. 2013 Feb 1;119(3):681-90. (PMID: <searchLink fieldCode="PM" term="%2222893254%22">22893254)</searchLink><br />Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7. (PMID: <searchLink fieldCode="PM" term="%2218947938%22">18947938)</searchLink><br />Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74. (PMID: <searchLink fieldCode="PM" term="%2217765406%22">17765406)</searchLink><br />Cancer. 1999 Jun 15;85(12):2630-7. (PMID: <searchLink fieldCode="PM" term="%2210375112%22">10375112)</searchLink><br />J Urol. 2016 Jun;195(6):1811-6. (PMID: <searchLink fieldCode="PM" term="%2226778712%22">26778712)</searchLink><br />Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85. (PMID: <searchLink fieldCode="PM" term="%2222954770%22">22954770)</searchLink><br />Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-53. (PMID: <searchLink fieldCode="PM" term="%2227325475%22">27325475)</searchLink><br />Radiother Oncol. 2000 Jan;54(1):11-9. (PMID: <searchLink fieldCode="PM" term="%2210719695%22">10719695)</searchLink><br />Radiat Oncol. 2014 Jan 01;9:1. (PMID: <searchLink fieldCode="PM" term="%2224382205%22">24382205)</searchLink><br />Br J Radiol. 2015 Oct;88(1054):20140736. (PMID: <searchLink fieldCode="PM" term="%2226235142%22">26235142)</searchLink><br />Int J Radiat Oncol Biol Phys. 2015 Aug 1;92 (5):971-7. (PMID: <searchLink fieldCode="PM" term="%2226054865%22">26054865)</searchLink><br />Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8. (PMID: <searchLink fieldCode="PM" term="%2224113055%22">24113055)</searchLink><br />Front Oncol. 2014 Oct 31;4:278. (PMID: <searchLink fieldCode="PM" term="%2225401085%22">25401085)</searchLink><br />J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7. (PMID: <searchLink fieldCode="PM" term="%2214610406%22">14610406)</searchLink><br />Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55. (PMID: <searchLink fieldCode="PM" term="%2217531401%22">17531401)</searchLink><br />Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16. (PMID: <searchLink fieldCode="PM" term="%2215817332%22">15817332)</searchLink><br />Radiat Oncol. 2014 Dec 12;9:277. (PMID: <searchLink fieldCode="PM" term="%2225497602%22">25497602)</searchLink><br />Radiother Oncol. 2009 May;91(2):232-6. (PMID: <searchLink fieldCode="PM" term="%2219097660%22">19097660)</searchLink><br />J Clin Oncol. 2007 Dec 1;25(34):5366-73. (PMID: <searchLink fieldCode="PM" term="%2218048817%22">18048817)</searchLink><br />JAMA. 2005 Sep 14;294(10):1233-9. (PMID: <searchLink fieldCode="PM" term="%2216160131%22">16160131)</searchLink><br />Front Oncol. 2015 Sep 01;5:194. (PMID: <searchLink fieldCode="PM" term="%2226389077%22">26389077)</searchLink><br />Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):184-91. (PMID: <searchLink fieldCode="PM" term="%2212694837%22">12694837)</searchLink><br />J Urol. 2007 Jan;177(1):123-7; discussion 127. (PMID: <searchLink fieldCode="PM" term="%2217162020%22">17162020)</searchLink>
– Name: GrantInfo
  Label: Grant Information
  Group: Grant
  Data: P30 CA051008 United States CA NCI NIH HHS
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: <i>Keywords: </i>CyberKnife; IMRT; SBRT; common terminology criteria; prostate cancer
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: <i>Date Created: </i>20170223 <i>Latest Revision: </i>20220408
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260130
– Name: PubmedCentralID
  Label: PubMed Central ID
  Group: ID
  Data: PMC5293802
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.3389/fonc.2017.00005
– Name: AN
  Label: PMID
  Group: ID
  Data: 28224113
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=28224113
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2017.00005
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5
    Titles:
      – TitleFull: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Paydar I
      – PersonEntity:
          Name:
            NameFull: Pepin A
      – PersonEntity:
          Name:
            NameFull: Cyr RA
      – PersonEntity:
          Name:
            NameFull: King J
      – PersonEntity:
          Name:
            NameFull: Yung TM
      – PersonEntity:
          Name:
            NameFull: Bullock EG
      – PersonEntity:
          Name:
            NameFull: Lei S
      – PersonEntity:
          Name:
            NameFull: Satinsky A
      – PersonEntity:
          Name:
            NameFull: Harter KW
      – PersonEntity:
          Name:
            NameFull: Suy S
      – PersonEntity:
          Name:
            NameFull: Dritschilo A
      – PersonEntity:
          Name:
            NameFull: Lynch JH
      – PersonEntity:
          Name:
            NameFull: Kole TP
      – PersonEntity:
          Name:
            NameFull: Collins SP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 02
              Text: 2017 Feb 07
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 7
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1